Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 209

Sort by

Sort Order Select

Journal Articles

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Ellen Marin, Sara Scott, Kathryn Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2023-189878

Published: 2023

Journal Articles

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Gurpanna Saggu, Min Young Lee, Faith Dunbar, Reshma Singh, Kris Sachsenmeier, Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Jonathan L. Kaufman, Adarsh Joshi, Kaveri Suryanarayan, Sabrina Collins

Blood (2023) 142 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2023-177909

Published: 2023

Journal Articles

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Marc S. Raab, Jonathan L. Kaufman, Shambavi Richard, Sebastian Grosicki, Istvan Takacs, Andras Strassz, Andreas Martin Pahl, Thorsten Michael, Anette Last, Hajnalka Szaboki, Garrit Jentsch, Oliver Schönborn-Kellenberger, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 3334.

https://doi.org/10.1182/blood-2023-182480

Published: 2023

Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2023-190279

Published: 2023

Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2023-181783

Published: 2023

Journal Articles

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Fredrik Schjesvold, Andrew Spencer, Yael C. Cohen, Enrique M Ocio, Jordi López-Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina Trabucco, Stan Ye, Romain Sechaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab

Blood (2023) 142 (Supplement 1): 4752.

https://doi.org/10.1182/blood-2023-177908

Published: 2023

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Nizar J Bahlis, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Niels Abildgaard, Jacob Laubach, Vincent Ribrag, Peter M. Voorhees, Xifeng Wang, Orlando Bueno, Yan Luo, Jeremy A Ross, Jonathan L. Kaufman

Blood (2023) 142 (Supplement 1): 338.

https://doi.org/10.1182/blood-2023-180766

Published: 2023

Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 647.

https://doi.org/10.1182/blood-2023-187339

Published: 2023

Journal Articles

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Jr., Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 1357–1359.

https://doi.org/10.1182/blood-2022-162253

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Blood (2022) 140 (Supplement 1): 244–245.

https://doi.org/10.1182/blood-2022-169558

Published: 2022

Journal Articles

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Jonathan L. Kaufman, Robert Z. Orlowski, Andras Strassz, Andreas Pahl, Thorsten Michaels, Anette Last, Hajnalka Szaboki, Garrit Jentsch, Oliver Schoenborn-Kellenberger, Marc-Steffen Raab

Blood (2022) 140 (Supplement 1): 7235–7236.

https://doi.org/10.1182/blood-2022-168848

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 7311–7312.

https://doi.org/10.1182/blood-2022-170062

Published: 2022

Journal Articles

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

R Donald Harvey, Joseph K Franz, Nisha S. Joseph, Jonathan L. Kaufman, Elise Hitron, Hannah Collins, Catherine Braga, Ludimila Cavalcante, Kathryn T. Maples, Craig C Hofmeister, Madhav Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2022) 140 (Supplement 1): 12633–12634.

https://doi.org/10.1182/blood-2022-157047

Published: 2022

Journal Articles

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Mohamed A Badawi, Benjamin Engelhardt, Jesus Badillo, Ahmed Abbas Suleiman, Leanne Lash Fleming, Yan Luo, Jonathan L. Kaufman, Nizar Jacques Bahlis, Rajeev Menon, Ahmed Hamed Salem

Blood (2022) 140 (Supplement 1): 10122–10123.

https://doi.org/10.1182/blood-2022-166429

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

NARROW

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only